Journals / İstanbul Kuzey Klinikleri / 2019 / Cilt: 6 - Sayı: 2

Apelin: A potential novel serum biomarker for early detection of diabetic nephropathy in patients with type 2 diabetes

Pages
151–155
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our resultsshow that the serum apelin levels were not correlated with the urine protein:creatinine ratio and provide further evidenceregarding the relationship between apelin and DN.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Diabetic nephropathy (DN) is the major cause of chronic renal failure, and proteinuria is an independentrisk factor for the end stage renal disease.
📊
Key Findings & Data:The random urine protein:creatinine ratio (P:C ratio) can accurately predict theamount of 24-hour urinary protein excretion.
💡
Conclusion & Impact:Our resultsshow that the serum apelin levels were not correlated with the urine protein:creatinine ratio and provide further evidenceregarding the relationship between apelin and DN.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Diabetic nephropathy (DN) is the major cause of chronic renal failure, and proteinuria is an independentrisk factor for the end stage renal disease. The random urine protein:creatinine ratio (P:C ratio) can accurately predict theamount of 24-hour urinary protein excretion. Apelin is thought to be associated with endothelial dysfunction, angiogenesis,and inflammation. This study investigated the apelin concentration and its association with the urine P:C ratio, and metabolicparameters in subjects with and without type 2 diabetes mellitus (T2D).METHODS: This study involved 86 subjects: 56 with newly diagnosed and untreated T2D and 30 non-diabetic controls. Allsubjects underwent a complete clinical examination that included anthropometric and laboratory measurements.RESULTS: Twenty-four males and sixty-two females participated in this study, and their mean age was 52.27±11.34 years.There were no differences in age, thyrotropin-stimulating hormone (TSH), creatinine clearance, and apelin levels betweengroups. As expected, fasting plasma glucose, weight, body mass index, and HbA1C were higher in T2D subjects (p=0.001,p=0.02, p=0.03, and p=0.001, respectively). Although apelin levels were higher in the control group, the differences were notstatistically significant (p=0.93). The P:C ratio levels were lower in the control group, and the differences were statistically significant (p=0.006). A Spearman correlation analysis revealed that serum apelin levels were not correlated with the urine P:C ratio.CONCLUSION: Our study demonstrates that T2D is associated with decreased serum apelin levels and increased urine P:Cratios compared to those in non-diabetic subjects. This association may depend on impaired glucose homeostasis. Our resultsshow that the serum apelin levels were not correlated with the urine protein:creatinine ratio and provide further evidenceregarding the relationship between apelin and DN.

🔖

Cite This Article

PAMUK, B. Ö., BAŞOK, B., YILMAZ, H., KARAKOYUN, İ., DEMİRPENÇE, M., COLAK, A. (2022). Apelin: A potential novel serum biomarker for early detection of diabetic nephropathy in patients with type 2 diabetes. İstanbul Kuzey Klinikleri, Cilt: 6 - Sayı: 2, 151–155. https://ajindex.com/articles/551459

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957– 72. [CrossRef ] 2. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433–42. 3. Methven S, MacGregor MS, Traynor JP, O’Reilly DS, Deighan CJ. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant 2010;25:2991–6. [CrossRef ] 4. Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J Kidney Dis 2009;53:S17–26. [CrossRef ] 5. Cirillo M. Evaluation of glomerular filtration rate and of albuminuria/ proteinuria. J Nephrol 2010;23:125–32. 6. Biradar SB, Kallaganad GS, Rangappa M, Kashinakunti SV, Retnakaran R. Correlation of spot urine protein-creatinine ratio with 24-hour urinary protein in type 2 diabetes mellitus patients: A cross sectional study. J Res Med Sci 2011;16:634–9. 7. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471–6. [CrossRef ] 8. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004;325:395–400. [CrossRef ] 9. Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol 2013;304:F788–800. 10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41. [CrossRef ] 11. Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care 2011;34:2374–8. 12. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 2013;433:359–61. [CrossRef ] 13. Habchi M, Duvillard L, Cottet V, Brindisi MC, Bouillet B, Beacco M, et al. Circulating apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control. Clin Endocrinol (Oxf ) 2014;81:696–701. [CrossRef ] 14. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006;114:544–8. [